Arturo Loaiza-Bonilla, MD, MSEd, FACP

The implementation of AI into radiomics may help predict the likelihood of response to therapies among patients undergoing breast cancer treatment.

Loaiza-Bonilla anticipates that AI-assisted EKG models could be cleared for use in risk stratification for receipt of surgery or drug use.

Artificial intelligence may be used in CT scans to help detect early-stage disease in at-risk patients undergoing screening for cancer.

AI-powered pathology imaging enables a more comprehensive assessment of tumor microenvironments than humans alone could perceive.

AI-powered tools may help alleviate doctor burnout and give clinicians more time to directly engage with patients.

Artificial intelligence may act as a force multiplier, with the automation of menial tasks enabling more time for clinicians to engage with patients.

Artificial intelligence may have the potential to enrich pathology practices to help identify aspects of tumor biology not seen with the human eye.

Efficacy results from the MASAI trial preceded the creation of the UK-funded EDITH trial, assessing 5 AI platforms in 700,000 women undergoing mammography.

An AI-based system may reduce the time needed to match patients with cancer to suitable clinical trials.